Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 4621 AL 4635

Approaches for treating cardiovascular symptoms in Parkinson's disease

Jost WH, Koschel J.

Ther Adv Neurol Disord. 2025 Sep 16;18:17562864251375181. doi: 10.1177/17562864251375181. eCollection 2025.

Free water predicts dementia with Lewy bodies in isolated REM sleep behavior disorder

Haddad C, Daneault V, Ayral V, Filiatrault M, Pastor-Bernier A, Tremblay C, Boré A, Descoteaux M, Vo A, Gagnon JF, Postuma RB, Dusek P, Marecek S, Varga Z, Klein J, Hu MT, Lehéricy S, Arnulf I, Vidailhet M, Corvol JC; ICEBERG Study Group; Rahayel S.

Alzheimers Dement. 2025 Sep;21(9):e70570. doi: 10.1002/alz.70570.

Recent synthetic advances in the preparation of 1,3-thiazole compounds and their therapeutic applications in degenerative diseases

Chaudhari P, Danta CC, Nefzi A.

Org Biomol Chem. 2025 Oct 22;23(41):9257-9284. doi: 10.1039/d5ob01199j.

Exosomes as Emerging Therapeutic Platforms in Neurological and Psychiatric Disorders

Kumar RMR, Rajan L, Chidambaram SB.

Pharmaceut Med. 2025 Nov;39(6):427-443. doi: 10.1007/s40290-025-00584-9. Epub 2025 Sep 19.

Reviving mitochondria to restore the mind: stem cell-based bioenergetic rescue in Parkinson's disease

Shidhaye S, Chaudhary AA, Gajghate M, Singanwad P, Umekar M, Raut N, Rudayni HA, Trivedi R.

Neurodegener Dis Manag. 2025 Sep 19:1-11. doi: 10.1080/17582024.2025.2562741. Online ahead of print.

Effects of monoclonal antibody therapies on depression in Parkinson's disease and Alzheimer's disease: Systematic review and meta-analysis

Gitlin-Leigh G, Wilson J, Howard R, Howard R, Costello H.

J Alzheimers Dis. 2025 Nov;108(2):500-508. doi: 10.1177/13872877251378156. Epub 2025 Sep 19.

Microglia and myeloperoxidase in neuroinflammatory and neurodegenerative diseases

Del Moro L, Brunetta E, Gershwin ME, Selmi C.

Curr Opin Immunol. 2025 Dec;97:102660. doi: 10.1016/j.coi.2025.102660. Epub 2025 Sep 18.

The Aggregation Continuum of α-Synuclein and Its Relevance to Brain Aging

Rana A, Nikam T, Sreepathi B, Saraf SA, Awasthi S.

ACS Chem Neurosci. 2025 Oct 1;16(19):3634-3652. doi: 10.1021/acschemneuro.5c00356. Epub 2025 Sep 20.

Nanoparticle-mediated magnetic hyperthermia in the treatment of neurological disorders

Naveed M, Kim MH.

Nanomedicine (Lond). 2025 Nov;20(22):2791-2803. doi: 10.1080/17435889.2025.2563499. Epub 2025 Sep 20.

Comment on 'Characteristics of the 18F-FDG and 18F-FP-DTBZ PET in patients with cognitive impairment in Parkinson's disease'

Sah R, Mehta R.

Clin Radiol. 2025 Nov;90:107057. doi: 10.1016/j.crad.2025.107057. Epub 2025 Aug 26.

Development and validation of a nomogram for predicting malnutrition risk among patients with Parkinson's disease: A retrospective cohort study

Tang Q, Ma W, Sun Y, Hu C, Ma S.

J Clin Neurosci. 2025 Dec;142:111635. doi: 10.1016/j.jocn.2025.111635. Epub 2025 Sep 19.

α-Synuclein seed amplification assay positivity beyond synucleinopathies

Martinez-Valbuena I, Fullam S, O'Dowd S, Tartaglia MC, Kovacs GG.

EBioMedicine. 2025 Oct;120:105925. doi: 10.1016/j.ebiom.2025.105925. Epub 2025 Sep 20.

Left bundle branch block on flecainide in Wolff-Parkinson-white syndrome

Mondal S, Lone MY, Muslim NA.

J Electrocardiol. 2025 Nov-Dec;93:154134. doi: 10.1016/j.jelectrocard.2025.154134. Epub 2025 Sep 17.

DJ-1/PARK7 in Parkinson's disease: mechanisms of pathogenesis and therapeutic potential

Bao W, Ge Y, Huang J, Li Y, Luo Y, Huang N.

Neuroscience. 2025 Nov 10;587:1-13. doi: 10.1016/j.neuroscience.2025.09.025. Epub 2025 Sep 19.

Stem cells therapy in neurodegenerative and neuroimmune diseases: Current status of treatments and future prospects

Shi M, Chu F, Zhu J.

Pharmacol Res. 2025 Nov;221:107960. doi: 10.1016/j.phrs.2025.107960. Epub 2025 Sep 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias